Michael Altman's Insider Trades & SAST Disclosures

Michael Altman's most recent trade in Arya Sciences Acquisition Corp IV - Ordinary Shares - Class A was a trade of 2,647,500 Class B ordinary shares done . Disclosure was reported to the exchange on July 31, 2024.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Arya Sciences Acquisition ...
Michael Altman Director, Chief Financial Officer, Ten Percent Owner Sale or transfer of securities back to the company at price $ 0.00 per share. 31 Jul 2024 2,647,500 0 - - Class B ordinary shares
Arya Sciences Acquisition ...
Michael Altman Director, Chief Financial Officer, Ten Percent Owner Sale or transfer of securities back to the company at price $ 0.00 per share. 31 Jul 2024 1,000,000 2,647,500 - - Class B ordinary shares
Arya Sciences Acquisition ...
Michael Altman Director, Chief Financial Officer, Ten Percent Owner Sale or transfer of securities back to the company at price $ 0.00 per share. 31 Jul 2024 499,000 0 - - Class A ordinary shares
Nautilus Biotechnology Inc
Michael Altman Director 14 Jun 2024 45,000 45,000 - - Stock Option (Right to Buy)
Perceptive Capital Solutio...
Michael Altman Director, Chief Business Officer, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 10.00 per share. 13 Jun 2024 286,250 286,250 - 10 2,862,500 Class A ordinary shares
Lyra Therapeutics Inc
Michael Altman Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Jun 2024 30,000 30,000 - - Stock Option
Lyra Therapeutics Inc
Michael Altman Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jun 2023 20,000 20,000 - - Stock Option
Nautilus Biotechnology Inc
Michael Altman Director 15 Jun 2023 45,000 45,000 - - Stock Option (Right to Buy)
Lyra Therapeutics Inc
Michael Altman Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 7,250 7,250 - - Stock Option
Nautilus Biotechnology Inc
Michael Altman Director 15 Jun 2022 86,467 86,467 - - Stock Option (Right to Buy)
Nautilus Biotechnology Inc
Michael Altman Director 09 Jun 2021 3,647,500 3,647,500 - - Common Stock
Nautilus Biotechnology Inc
Michael Altman Director 09 Jun 2021 3,647,500 0 - - Class B ordinary shares
Nautilus Biotechnology Inc
Michael Altman Director 09 Jun 2021 499,000 499,000 - - Common Stock
Nautilus Biotechnology Inc
Michael Altman Director 09 Jun 2021 499,000 0 - - Class A ordinary shares
Nautilus Biotechnology Inc
Michael Altman Director 09 Jun 2021 44,435 44,435 - - Stock Option (Right to buy)
Lyra Therapeutics Inc
Michael Altman Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 May 2021 7,250 7,250 - - Stock Option
Arya Sciences Acquisition ...
Michael Altman Director, Chief Financial Officer, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 10.00 per share. 02 Mar 2021 499,000 499,000 - 10 4,990,000 Class A ordinary shares
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades